Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.4
2.4
Journals
JCDD
Special Issues
Prevention and Management of Heart Failure
share announcement

Prevention and Management of Heart Failure

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Electrophysiology and Cardiovascular Physiology".

Deadline for manuscript submissions: closed (20 March 2024) | Viewed by 2978

Special Issue Editors

Dr. Raymond C. C. Wong

E-Mail Website
Guest Editor
Department of Cardiology, National University Heart Centre, Singapore 119228, Singapore.
Interests: heart failure; cardiomyopathy; cardiac imaging; nuclear cardiology; echocardiography; quality improvement
Dr. Weiqin Lin

E-Mail Website
Guest Editor
Department of Cardiology, National University Heart Centre, Singapore 119228, Singapore.
Interests: advanced heart failure; mechanical circulatory support; invasive haemodynamics; cardiomyopathies; cardiac amyloidosis; cardiac sarcoidosis; echocardiography; heart transplantation

Special Issue Information

Dear Colleagues,

Heart failure is a prevalent condition that carries high morbidity and mortality. With aging populations in many societies, as well as improved survival of ischemic and valvular heart diseases through treatment advances, the ‘tsunami’ of heart failure is but round the corner. The key to curtailing the rapid rise of heart failure incidence lies in effective prevention that is evidence-based and methodical. This focuses on early identification of heart failure risk factors such as hypertension and diabetes, improved proven and novel therapies that aim to reverse/remodel left ventricular functions after myocardial infarctions, as well as early detection of incipient heart failure within the community, particularly among diabetics. For patients who manifest clinical heart failure, multidisciplinary approaches anchored on guideline-driven medical therapies and implantable devices can reduce incidences of worsening heart failure, hospitalization, and mortality. 

The aim of this Special Issue is therefore to systematically review the latest pharmacological and device advances in heart failure that modify disease progression and improve quality of life, to discuss practical approaches and challenges to heart failure prevention, including the use of biomarkers in the detection of preclinical stages of the disease, and to review novel therapies on the horizon.

Dr. Raymond C. C. Wong
Dr. Weiqin Lin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • heart failure
  • guideline-driven medical therapy
  • implantable devices
  • prevention
  • novel therapies
  • multidisciplinary approach

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1474 KiB  
Article
The Impact of Acute Heart Failure on Frailty Degree and Outcomes in Elderly Patients with Severe Aortic Stenosis and Chronic Heart Failure with Preserved Ejection Fraction
by Augusto Esposito, Ilenia Foffa, Cecilia Vecoli, Luca Bastiani, Sergio Berti and Annamaria Mazzone
J. Cardiovasc. Dev. Dis. 2024, 11(5), 150; https://doi.org/10.3390/jcdd11050150 - 14 May 2024
Viewed by 239
Abstract
Frailty degree plays a critical role in the decision-making and outcomes of elderly patients with severe aortic stenosis (AS). Acute heart failure (AHF) results in a severely worse clinical hemodynamic status in this population. This study aimed to evaluate the impact of AHF [...] Read more.
Frailty degree plays a critical role in the decision-making and outcomes of elderly patients with severe aortic stenosis (AS). Acute heart failure (AHF) results in a severely worse clinical hemodynamic status in this population. This study aimed to evaluate the impact of AHF on frailty degree and outcomes in older patients referred for tailored interventional treatment due to AS. A total of 109 patients (68% female; mean age 83.3 ± 5.4), evaluated by a multidisciplinary path for “frailty-based management” of valve disease, were divided into two groups, one with (AHF+) and one without AHF (AHF-) and preserved ejection fraction (mean value EF: 57.4 ± 8.6). AHF occurred a mean value of 55 days before geriatric, clinical, and surgical assessment. A follow-up for all-cause mortality and readmission was conducted at 20 months. AHF+ patients showed a higher frequency of advanced frailty (53.3% vs. 46.7%, respectively), rehospitalization (35.5% vs. 12.8; p = 0.007), and death (41.9% vs. 12.8%; p < 0.001). In stepwise logistic regression analysis, AHF emerged as an independent risk factor for advanced frailty (OR: 3.8 CI 1.3–10.7; p = 0.01) and hospital readmission (OR: 3.6 CI 1.1–11.6; p = 0.03). In addition, preceding AHF was an independent determinant associated with a higher risk of mortality (HR 2.65; CI 95% 1.04–6.74; p-value 0.04). AHF is independently associated with advanced frailty and poor outcomes in elderly patients with severe AS. So, this population needs careful clinical and geriatric monitoring and the implementation of interventional therapy for AS in the early stages of frailty to avoid the occurrence of AHF and poor outcomes. Full article
(This article belongs to the Special Issue Prevention and Management of Heart Failure)
►▼ Show Figures

Figure 1

Review

Jump to: Research

12 pages, 774 KiB  
Review
Heartfelt Breakthroughs: Elevating Quality of Life with Cutting-Edge Advances in Heart Failure Treatment
by Ramprakash Devadoss, Gagandeep Dhillon, Pranjal Sharma, Ram Kishun Verma, Ripudaman Munjal and Rahul Kashyap
J. Cardiovasc. Dev. Dis. 2024, 11(1), 15; https://doi.org/10.3390/jcdd11010015 - 5 Jan 2024
Viewed by 2019
Abstract
Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure [...] Read more.
Heart failure is a cardiovascular condition, leading to fatigue, breathlessness, and fluid retention. It affects around 56 million people globally and is a leading cause of hospitalization and mortality. Its prevalence is rising due to aging populations and lifestyle factors. Managing heart failure demands a multidisciplinary approach, encompassing medications, lifestyle modifications, and often medical devices or surgeries. The treatment burden is substantial, impacting patients’ daily lives and straining healthcare systems. Improving early detection, novel therapies, and patient education are crucial for alleviating the burden and enhancing the quality of life. There are notable advancements in the field of heart failure treatment and prevention. We will discuss significant pharmacological and device advances related to heart failure, including angiotensin receptor–neprilysin inhibitor, sodium–glucose co-transporter inhibition, glucagon-like peptide-1 agonist, cardiac resynchronization therapy, cardiac contractility modulation, mechanical circulatory support devices, and transcatheter valve interventions. We will also review novel therapies on the horizon, emerging technologies like CRISPR-based treatments for genetic anomalies, and the involvement of artificial intelligence in heart failure detection and management. Full article
(This article belongs to the Special Issue Prevention and Management of Heart Failure)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop